In Vitro Susceptibilities of Clinical Yeast Isolates to the New Antifungal Eberconazole Compared with Their Susceptibilities to Clotrimazole and Ketoconazole | Zendy

Josep M. Torres-Rodrı́guez | Zendy; R Méndez | Zendy; Olga López-Jodra | Zendy; Yolanda Morera | Zendy; Mateu Espasa | Zendy; Teresa Jiménez | Zendy; Carme Lagunas | Zendy

Open Access

In Vitro Susceptibilities of Clinical Yeast Isolates to the New Antifungal Eberconazole Compared with Their Susceptibilities to Clotrimazole and Ketoconazole

Author(s) -

Josep M. Torres-Rodrı́guez,

R Méndez,

Olga López-Jodra,

Yolanda Morera,

Mateu Espasa,

Teresa Jiménez,

Carme Lagunas

Publication year - 1999

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.43.5.1258

Subject(s) - clotrimazole , ketoconazole , candida krusei , microbiology and biotechnology , biology , antifungal , antifungal drugs , cryptococcus neoformans , candida glabrata , miconazole , fluconazole

The antifungal activity of eberconazole, a new imidazole derivative, against 124 clinical isolates of Candida comprising eight different species and to 34 isolates of Cryptococcus neoformans was compared to those of clotrimazole and ketoconazole. MICs of eberconazole, determined by the National Committee for Clinical Laboratory Standards standardized microbroth method, were equal to or lower than those of other azoles, especially for Candida krusei and Candida glabrata, which are usually resistant to triazoles.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research